USA –DarioHealth Corp., a global digital therapeutics (DTx) provider, announced a US$30 million multi-year strategic agreement with Sanofi U.S., an innovative global healthcare company.

The multi-year, US $30 million agreement will aid in the commercialization of Dario’s full suite of digital therapeutics and the expansion of digital health solutions on the Dario platform.

As part of the strategic agreement, Dario and Sanofi will work together to promote the Dario multi-condition digital therapeutics solution, significantly increasing Dario’s sales reach in the health plan market and, to a lesser extent, in the employer channel.

The companies see the collaboration as a way to accelerate adoption of digital therapeutics for chronic conditions, which are common in the United States and account for the majority of healthcare spending.

Dario’s platform includes tools for managing diabetes, hypertension, weight, musculoskeletal disorders, and behavioral health issues.

In addition, the agreement calls for Dario and Sanofi to develop new or enhanced solutions leveraging the Dario platform, and for the parties to generate robust evidence to support future commercialization in the health plan channel. 

Our collaboration with Dario is another step towards accelerating Sanofi’s mission of reversing the course of chronic diseases through the integration of healthcare and technology in a way that gives people the tools to improve their health.”

Gustavo Pesquin, head of U.S. general medicines at Sanofi.


This isn’t the first time that digital health and pharmaceuticals have collaborated. Earlier this year, Alex Therapeutics, a Swedish startup, announced a strategic commercial agreement with Pfizer to develop digital therapeutics for nicotine addiction, initially in Germany.

23andMe, a consumer genetics company, recently extended their drug discovery partnership with GlaxoSmithKline, which began in 2018.

Pear Therapeutics had a commercialization partnership with Novartis for its reSET and reSET-O prescription digital therapeutics, which was terminated in 2019.

Sanofi signed a deal with Happify Health in 2019 to treat anxiety and depression in patients with multiple sclerosis.

It also recently signed an agreement with Exscientia to collaborate on AI-enabled drug discovery.

Meanwhile, Dario has been broadening the clinical scope of its platform. It entered the digital MSK space in January 2021 by acquiring Upright Technologies, and its tool, Dario Move, was released in October.

In May, it also acquired digital mental health company wayForward.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE